• CalciMedica announced a private placement financing for up to $49 million in gross proceeds through the sale of common stock and warrants, a move that is weighing on share value.
  • Separately, the FDA has completed its review of a protocol amendment and interim safety data for the Phase 2 KOURAGE trial in acute kidney injury (AKI) and provided no comments, allowing dosing to continue. This contradicts the previous understanding of trial discontinuation causing pressure.